TSHA
Taysha Gene Therapies Inc
NASDAQ: TSHA · HEALTHCARE · BIOTECHNOLOGY
$6.39
+1.91% today
Updated 2026-04-30
Market cap
$1.80B
P/E ratio
—
P/S ratio
184.35x
EPS (TTM)
$-0.34
Dividend yield
—
52W range
$2 – $7
Volume
2.8M
Taysha Gene Therapies Inc (TSHA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $135000.00 | $-30.73M | $-117.04M | $-88.39M | $-73.02M | $-81.22M | $-93.09M |
| Capital expenditures | $82000.00 | $9.08M | $21.55M | $24.87M | $7.37M | $374000.00 | $738000.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | — | $3.35M | $18.18M | $18.04M | $7.91M | $13.10M | $13.30M |
| Free cash flow | $53000.00 | $-39.81M | $-138.60M | $-113.26M | $-80.39M | $-81.60M | $-93.83M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | $251.25M | — | — | — | — | — |